Intellia Therapeutics Inc [NASDAQ: NTLA] slipped around -1.35 points on Tuesday, while shares priced at $14.99 at the close of the session, down -8.26%.
Compared to the average trading volume of 1.68M shares, NTLA reached a trading volume of 4539564 in the most recent trading day, which is why market watchdogs consider the stock to be active.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
What do top market gurus say about Intellia Therapeutics Inc [NTLA]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for NTLA shares is $64.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on NTLA stock is a recommendation set at 1.50. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Goldman have made an estimate for Intellia Therapeutics Inc shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on February 23, 2024. While these analysts kept the previous recommendation, Wolfe Research raised their target price to Peer Perform. The new note on the price target was released on February 15, 2024, representing the official price target for Intellia Therapeutics Inc stock. Previously, the target price had yet another raise to $66, while Canaccord Genuity analysts kept a Buy rating on NTLA stock.
The Average True Range (ATR) for Intellia Therapeutics Inc is set at 1.26, with the Price to Sales ratio for NTLA stock in the period of the last 12 months amounting to 33.12. The Price to Book ratio for the last quarter was 1.52, with the Price to Cash per share for the same quarter was set at 6.80.
How has NTLA stock performed recently?
Intellia Therapeutics Inc [NTLA] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -28.89. With this latest performance, NTLA shares dropped by -27.06% in over the last four-week period, additionally sinking by -29.95% over the last 6 months – not to mention a drop of -35.28% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for NTLA stock in for the last two-week period is set at 29.39, with the RSI for the last a single of trading hit 24.90, and the three-weeks RSI is set at 32.61 for Intellia Therapeutics Inc [NTLA]. The present Moving Average for the last 50 days of trading for this stock 20.42, while it was recorded at 16.61 for the last single week of trading, and 23.99 for the last 200 days.
Intellia Therapeutics Inc [NTLA]: Deeper insight into the fundamentals
Intellia Therapeutics Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 7.21 and a Current Ratio set at 7.21.
Earnings analysis for Intellia Therapeutics Inc [NTLA]
With the latest financial reports released by the company, Intellia Therapeutics Inc posted -1.38/share EPS, while the average EPS was predicted by analysts to be reported at -1.5/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 0.12. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for NTLA. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Intellia Therapeutics Inc go to 30.00%.
Insider trade positions for Intellia Therapeutics Inc [NTLA]
There are presently around $87.10%, or 88.16%% of NTLA stock, in the hands of institutional investors. The top three institutional holders of NTLA stocks are: ARK INVESTMENT MANAGEMENT LLC with ownership of 11.6 million shares, which is approximately 12.1419%. BLACKROCK INC., holding 9.6 million shares of the stock with an approximate value of $$214.79 million in NTLA stocks shares; and BLACKROCK INC., currently with $$203.66 million in NTLA stock with ownership which is approximately 9.5287%.
